1.Aplastic Anemia.
Korean Journal of Pediatrics 2004;47(Suppl 2):S242-S256
No abstract available.
Anemia, Aplastic*
2.Angiogenesis of Retina in Diabetic Retinopathy.
Journal of Korean Society of Endocrinology 2001;16(3):339-351
No abstract available.
Diabetic Retinopathy*
;
Retina*
3.Platelet-rich Plasma in Arthroscopic Rotator Cuff Repair.
Clinics in Shoulder and Elbow 2015;18(2):113-118
Rotator cuff tear is a common reason for shoulder pain. Although the surgical technique of rotator cuff repair is developing, high retear rate requires additional supplementary methods. Among these supplementary methods, as a kind of biologic augmentation, platelet-rich plasma (PRP) has been spotlighted and has recently been studied by many researchers. PRP, a concentrate of platelet extract obtained from whole blood, contains numerous growth factors. As this is known to play an important role in the tissue recovery process, it had been used for research in a variety of fields including orthopedics. Use of PRP has been attempted in surgical treatments of rotator cuff tear for better results; however, only a few large-scale research studies on the effect of PRP have been reported. Clinical results of each study are also variable. Therefore research using large-scale randomized, double-blind trials should be conducted in order to prove the application range, safety, and clinical effects of PRP.
Blood Platelets
;
Intercellular Signaling Peptides and Proteins
;
Orthopedics
;
Platelet-Rich Plasma*
;
Rotator Cuff*
;
Shoulder
;
Shoulder Pain
4.In Honor of the JKMA.
Journal of the Korean Medical Association 2004;47(1):4-5
No abstract available.
5.Electronic publication of research results.
Restorative Dentistry & Endodontics 2012;37(2):67-67
No abstract available.
Electronics
;
Electrons
;
Publications
6.Problem-based learning.
Journal of the Korean Academy of Family Medicine 2000;21(5):602-612
No abstract available.
Problem-Based Learning*
7.New Antimicrobial Agents for Treatment of Community-Acquired Pneumonia.
Tuberculosis and Respiratory Diseases 2001;50(2):147-157
No abstract available.
Anti-Infective Agents*
;
Pneumonia*
8.A case report as an inductive approach.
Restorative Dentistry & Endodontics 2012;37(4):187-187
No abstract available.
9.A Study of Depression in Positive and Negative Schizaphrenics.
Yeungnam University Journal of Medicine 1994;11(2):338-351
This study was to find out whether there were differences in the levels of depressions between positive and negative schizophrenics. This research was derived from the fact that negative schizophrenics show higher levels of depression than positive schizophrenics. This study also examined the levels of psychomotor dysfunction in positive and negative schizophrenics. For this study, there were 453 subjects. They consisted of 119 positive schizophrenics, 122 negative schizophrenics and 212 normal people. They were asked to complete Zung's Self-Rating Depression Scale(SDS) and to perform one subtest, Digit Symbol of KWIS(Korean Wechsler Intelligence SCALE). Subjects levels of depression were measured by the SDS. The level of psychomotor dysfunction was measured by Digit Symbol subtest of Korean Wechsler Intelligence Scale. ANOVA and Duncan's multiple comparison analysis were used to examine whether there were differences of depression and psychomotor dysfunction among the normal people, positive and negative schizophrenics. The results were as follows ; It was found that the depression level was higher in the negative schizophrenic patients than positive schizophrenic patients. Levels of depression were significantly higher in negative schizophrenics than positive schizophrenics. Psychomotor retardation symptom was the most effective variable that discriminates between the normals and the schizophrenics. And it would be concluded that the psychomotor dysfunction was more severe in negative schizophrenics than positive schizophrenics.
Depression*
;
Humans
;
Intelligence
10.Percutaneous Coronary Intervention.
Journal of the Korean Medical Association 2002;45(5):567-574
Since the introduction of percutaneous balloon angioplasty by Gruentzig in 1979, percutaneous coronary intervention (PCI) has become the main treatment modality for the management of coronary heart disease. More than 1,000,000 PCI procedures are performed annually worldwide. With the advent of new therapeutic technologies, the indications for PCI have markedly expanded. Nowadays, improvements in balloon technology, popular use of coronary stent, and the proper administration of antiplatelet agents including GPIIbIIIa inhibitors have influenced the acute procedural outcomes. This technological and procedural advance in PCI has resulted in angiographic success rates of 96 to 99%, with Q-wave MI rates of 1 to 3%, emergency coronary bypass surgery rates of 0.2 to 3%, and unadjusted in-hospital mortality rates of 0.5~1.4%. However, despite the marked improvements in the acute outcome of PCI, long-term results including the restenosis rate are less impressive. The restenosis rate following balloon angioplasty reaches 30~40%, and is higher in certain clinical and angiographic subsets. The recent introduction of intracoronary stent and brachytherapy (intracoronary lesional ionizing radiation therapy) has a favorable impact on the restenosis precess including elastic recoil and intimal hyperplasia. Intracoronary stents decreased elastic recoil and remodeling and intracoronary radiation reduced intimal hyperplasia. Several randomized clinical trials to assess the efficacy of stents and intracoronary brachytherapy are ongoing with impressive results. In 2001, a breakthrough has been made in the prevention and the treatment of restenosis with the advent of a drug-eluting stent. Balloon-expandable stents coated with rapamycin or paclitaxol showed nearly 0% restenosis rate at 6-month follow-up. We might expect to solve restenosis completely in a very near future.
Angioplasty, Balloon
;
Brachytherapy
;
Coronary Disease
;
Drug-Eluting Stents
;
Emergencies
;
Follow-Up Studies
;
Hospital Mortality
;
Hyperplasia
;
Percutaneous Coronary Intervention*
;
Platelet Aggregation Inhibitors
;
Radiation, Ionizing
;
Sirolimus
;
Stents